anesthesia and semaglutide Your patient took this week. Cancel the EGD, proceed, or risk-stratify? The OCULUS randomized trial found clinically significant residual gastric volume was higher when GLP-1/GIP agonists were continued vs held for New Study Recommends Stopping GLP-1

The gastrointestinal side effect profile was consistent with the GLP-1 agonist class: Nausea (most common, generally transient) Vomiting Diarrhea Decreased appetite Constipation These adverse events were described as generally mild and infrequently led to treatment discontinuation

Lets explore how semaglutide, non-surgical fat reduction, and plastic surgery all work together (or dont)

Scatter plot showing a 2D-projection of all discussion embeddings, where each point represents a discussion

This creates a vicious cycle where metabolic dysfunction perpetuates further insulin resistance

Mechanistic support primarily comes from cellular and animal studies, which demonstrate that EGT protects endothelial cells from oxidative stress and may limit ischemiareperfusion damage and vascular dysfunction, rather than from large-scale human intervention trials

However, until a dedicated outcomes trial confirms these benefits translate to fewer heart attacks and strokes, Semaglutide remains the only option with proven cardiovascular event reduction